Theresa Falls

List of Publications by Year
in descending order

45 papers	3,586 citations	159358 30 h-index	233125 45 g-index
45 all docs	45 docs citations	45 times ranked	3849 citing authors

#	Article	IF	Citations
1	Perk-Dependent Translational Regulation Promotes Tumor Cell Adaptation and Angiogenesis in Response to Hypoxic Stress. Molecular and Cellular Biology, 2006, 26, 9517-9532.	1.1	264
2	Targeted Inflammation During Oncolytic Virus Therapy Severely Compromises Tumor Blood Flow. Molecular Therapy, 2007, 15, 1686-1693.	3.7	242
3	Neoadjuvant oncolytic virotherapy before surgery sensitizes triple-negative breast cancer to immune checkpoint therapy. Science Translational Medicine, 2018, 10, .	5.8	242
4	The Oncolytic Poxvirus JX-594 Selectively Replicates in and Destroys Cancer Cells Driven by Genetic Pathways Commonly Activated in Cancers. Molecular Therapy, 2012, 20, 749-758.	3.7	231
5	Preventing Postoperative Metastatic Disease by Inhibiting Surgery-Induced Dysfunction in Natural Killer Cells. Cancer Research, 2013, 73, 97-107.	0.4	187
6	Carrier Cell-based Delivery of an Oncolytic Virus Circumvents Antiviral Immunity. Molecular Therapy, 2007, 15, 123-130.	3.7	171
7	Chemical targeting of the innate antiviral response by histone deacetylase inhibitors renders refractory cancers sensitive to viral oncolysis. Proceedings of the National Academy of Sciences of the United States of America, 2008, 105, 14981-14986.	3.3	161
8	Targeting Tumor Vasculature With an Oncolytic Virus. Molecular Therapy, 2011, 19, 886-894.	3.7	149
9	Identification of Genetically Modified Maraba Virus as an Oncolytic Rhabdovirus. Molecular Therapy, 2010, 18, 1440-1449.	3.7	127
10	Sequential Therapy With JX-594, A Targeted Oncolytic Poxvirus, Followed by Sorafenib in Hepatocellular Carcinoma: Preclinical and Clinical Demonstration of Combination Efficacy. Molecular Therapy, 2011, 19, 1170-1179.	3.7	122
11	A let-7 MicroRNA-sensitive Vesicular Stomatitis Virus Demonstrates Tumor-specific Replication. Molecular Therapy, 2008, 16, 1437-1443.	3.7	121
12	Reciprocal cellular cross-talk within the tumor microenvironment promotes oncolytic virus activity. Nature Medicine, 2015, 21, 530-536.	15.2	118
13	Synergistic Interaction Between Oncolytic Viruses Augments Tumor Killing. Molecular Therapy, 2010, 18, 888-895.	3.7	109
14	Re-engineering Vesicular Stomatitis Virus to Abrogate Neurotoxicity, Circumvent Humoral Immunity, and Enhance Oncolytic Potency. Cancer Research, 2014, 74, 3567-3578.	0.4	100
15	Virus-Tumor Interactome Screen Reveals ER Stress Response Can Reprogram Resistant Cancers for Oncolytic Virus-Triggered Caspase-2 Cell Death. Cancer Cell, 2011, 20, 443-456.	7.7	87
16	Surgical Stress Promotes the Development of Cancer Metastases by a Coagulation-Dependent Mechanism Involving Natural Killer Cells in a Murine Model. Annals of Surgery, 2013, 258, 158-168.	2.1	87
17	A High-throughput Pharmacoviral Approach Identifies Novel Oncolytic Virus Sensitizers. Molecular Therapy, 2010, 18, 1123-1129.	3.7	85
18	VEGF-Mediated Induction of PRD1-BF1/Blimp1 Expression Sensitizes Tumor Vasculature to Oncolytic Virus Infection. Cancer Cell, 2015, 28, 210-224.	7.7	77

#	Article	IF	Citations
19	Combination of Paclitaxel and MG1 oncolytic virus as a successful strategy for breast cancer treatment. Breast Cancer Research, 2016, 18, 83.	2.2	73
20	Harnessing Oncolytic Virus-mediated Antitumor Immunity in an Infected Cell Vaccine. Molecular Therapy, 2012, 20, 1791-1799.	3.7	70
21	Complement Inhibition Prevents Oncolytic Vaccinia Virus Neutralization in Immune Humans and Cynomolgus Macaques. Molecular Therapy, 2015, 23, 1066-1076.	3.7	65
22	Protein arginine methyltransferase 7 promotes breast cancer cell invasion through the induction of MMP9 expression. Oncotarget, 2015, 6, 3013-3032.	0.8	65
23	Oncolytic vesicular stomatitis virus expressing interferon-Ïƒ has enhanced therapeutic activity. Molecular Therapy - Oncolytics, 2016, 3, 16001.	2.0	63
24	Enhancement of Vaccinia Virus Based Oncolysis with Histone Deacetylase Inhibitors. PLoS ONE, 2010, 5, e14462.	1.1	63
25	Maraba MG1 Virus Enhances Natural Killer Cell Function via Conventional Dendritic Cells to Reduce Postoperative Metastatic Disease. Molecular Therapy, 2014, 22, 1320-1332.	3.7	60
26	ORFV: A Novel Oncolytic and Immune Stimulating Parapoxvirus Therapeutic. Molecular Therapy, 2012, 20, 1148-1157.	3.7	59
27	Microtubule disruption synergizes with oncolytic virotherapy by inhibiting interferon translation and potentiating bystander killing. Nature Communications, 2015, 6, 6410.	5.8	42
28	Double-Stranded RNAâ€“Dependent Protein Kinase Deficiency Protects the Heart From Systolic Overload-Induced Congestive Heart Failure. Circulation, 2014, 129, 1397-1406.	1.6	41
29	Model-based rational design of an oncolytic virus with improved therapeutic potential. Nature Communications, 2013, 4, 1974.	5.8	38
30	Bacterial-Mediated Knockdown of Tumor Resistance to an Oncolytic Virus Enhances Therapy. Molecular Therapy, 2014, 22, 1188-1197.	3.7	37
31	Clonal variation in interferon response determines the outcome of oncolytic virotherapy in mouse CT26 colon carcinoma model. Gene Therapy, 2015, 22, 65-75.	2.3	30
32	Potent Oncolytic Activity of Raccoonpox Virus in the Absence of Natural Pathogenicity. Molecular Therapy, 2010, 18, 896-902.	3.7	27
33	Leukemia Cell-Rhabdovirus Vaccine: Personalized Immunotherapy for Acute Lymphoblastic Leukemia. Clinical Cancer Research, 2013, 19, 3832-3843.	3.2	27
34	Enhancing Expression of Functional Human Sodium Iodide Symporter and Somatostatin Receptor in Recombinant Oncolytic Vaccinia Virus for In Vivo Imaging of Tumors. Journal of Nuclear Medicine, 2017, 58, 221-227.	2.8	21
35	Resistance to Two Heterologous Neurotropic Oncolytic Viruses, Semliki Forest Virus and Vaccinia Virus, in Experimental Glioma. Journal of Virology, 2013, 87, 2363-2366.	1.5	19
36	Tudor Domain Containing Protein 3 Promotes Tumorigenesis and Invasive Capacity of Breast Cancer Cells. Scientific Reports, 2017, 7, 5153.	1.6	18

#	Article	IF	Citations
37	Non-replicating rhabdovirus-derived particles (NRRPs) eradicate acute leukemia by direct cytolysis and induction of antitumor immunity. Blood Cancer Journal, 2013, 3, e123-e123.	2.8	15
38	Different ODE models of tumor growth can deliver similar results. BMC Cancer, 2020, 20, 226.	1.1	14
39	Complement inhibition enables tumor delivery of LCMV glycoprotein pseudotyped viruses in the presence of antiviral antibodies. Molecular Therapy - Oncolytics, 2016, 3, 16027.	2.0	11
40	Oncolytic Vaccinia virus safely and effectively treats skin tumors in mouse models of xeroderma pigmentosum. International Journal of Cancer, 2013, 132, 726-731.	2.3	10
41	Programmable insect cell carriers for systemic delivery of integrated cancer biotherapy. Journal of Controlled Release, 2015, 220, 210-221.	4.8	10
42	Murine Tumor Models for Oncolytic Rhabdo-Virotherapy. ILAR Journal, 2016, 57, 73-85.	1.8	10
43	Expression of the fusogenic p14 FAST protein from a replication-defective adenovirus vector does not provide a therapeutic benefit in an immunocompetent mouse model of cancer. Cancer Gene Therapy, 2016, 23, 355-364.	2.2	8
44	Adenovirus-Mediated Expression of the p14 Fusion-Associated Small Transmembrane Protein Promotes Cancer Cell Fusion and Apoptosis In Vitro but Does Not Provide Therapeutic Efficacy in a Xenograft Mouse Model of Cancer. PLoS ONE, 2016, 11, e0151516.	1.1	7
45	In vivo characterization of [18F]AVT-011 as a radiotracer for PET imaging of multidrug resistance. European Journal of Nuclear Medicine and Molecular Imaging, 2020, 47, 2026-2035.	3.3	3